Pharvaris Announces $70 Million Private Placement Financing
Summary
, (GLOBE NEWSWIRE) -- (Nasdaq: ), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that it has entered into a subscription agreement relating to the offer and sale of an aggregate of 6,951,340 ordinary shares of the Company, par value 0.12 per share (the Ordinary Shares), in a private placement (the Offering) to a group of institutional investors, led by General and venBio Partners with participation from Bain Capital Life Sciences, , and , at an offering price of per share, for gross proceeds of approximately before deducting any offering-related expenses.The Offering is expected to close on or about , subject to customary closing conditions.intends to use the net proceeds from the Offering to fund research and development and product discovery expenses, and for working capital and general corporate purposes.The offer and sale of the Ordinary Shares have not been, and will not be, registered under the Securities Act of 1933, as amended (the Securities Act), or any other securities laws, and the Ordinary Shares cannot be offered or sold in except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities, in any state or jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Building on its deep-seated roots in HAE, is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks. These forward-looking statements are based on managements current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While may elect to update such forward-looking statements at some point in the future, disclaims any obligation to do so, even if subsequent events cause its views to change.